Last $133.84 USD
Change Today +0.55 / 0.41%
Volume 1.9M
SLXP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (SLXP) Snapshot

Open
$129.49
Previous Close
$133.29
Day High
$136.98
Day Low
$129.49
52 Week High
07/2/14 - $141.81
52 Week Low
08/28/13 - $64.93
Market Cap
8.5B
Average Volume 10 Days
1.9M
EPS TTM
$1.93
Shares Outstanding
63.4M
EX-Date
--
P/E TM
69.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for SALIX PHARMACEUTICALS LTD (SLXP)

salix pharmaceuticals ltd (SLXP) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (SLXP) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (SLXP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $867.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $488.9K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (SLXP) Key Developments

Cosmo Technologies Ltd, Salix Pharmaceuticals Ltd. - M&A Call

To discuss on company's definitive merger agreement with Cosmo Technologies Limited

Salix Pharmaceuticals Ltd. Announces Primary Endpoint Result for Target 3 Evaluating the Efficacy and Safety of Repeat Treatment with Rifaximin 550mg in Subjects with Irritable Bowel Syndrome with Diarrhea

Salix Pharmaceuticals Ltd. announced the outcome of TARGET 3 -a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg TID (three times daily) for 14 days in subjects with irritable bowel syndrome with diarrhea, or IBS-D, who respond to an initial treatment course with rifaximin 550 mg TID for 14 days. In the study a statistically significant greater proportion of rifaximin treated subjects (as compared to placebo) responded to repeat treatment as assessed by the composite primary endpoint of IBS-related abdominal pain and stool consistency during the 4 week treatment-free follow-up period (Primary Evaluation Period, or PEP) in the Double Blind Repeat Treatment Phase. XIFAXAN(R) (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients >= 18 years of age. XIFAXAN (rifaximin) 550 mg tablets are contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis. Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon which may lead to overgrowth of C. difficile. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. There is increased systemic exposure in patients with more severe hepatic dysfunction. The clinical trials were limited to patients with MELD scores < 25. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C). Concomitant administration of drugs that are P-glycoprotein (P-gp) inhibitors with XIFAXAN can substantially increase the systemic exposure to XIFAXAN. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to XIFAXAN. Based on animal data, XIFAXAN may cause fetal harm. Discontinue in nursing mothers after taking into account the importance of the drug to the mother. The most common adverse reactions occurring in >= 10% of patients and at a higher incidence than placebo in the clinical study were peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%).

Salix Pharmaceuticals Ltd. Approves Amendment to Certificate of Incorporation

Salix Pharmaceuticals Ltd. announced that it has approved amendment to Certificate of Incorporation to increase the total number of authorized shares of capital stock from 155,000,000 shares to 305,000,000 shares and to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares, at its AGM held on June 13, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLXP:US $133.84 USD +0.55

SLXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $47.80 USD -0.91
Cubist Pharmaceuticals Inc $67.92 USD -0.42
Jazz Pharmaceuticals Plc $152.49 USD -2.21
Lupin Ltd 1,039 INR 0.00
Ono Pharmaceutical Co Ltd ¥8,860 JPY +50.00
View Industry Companies
 

Industry Analysis

SLXP

Industry Average

Valuation SLXP Industry Range
Price/Earnings 100.0x
Price/Sales 7.6x
Price/Book 11.9x
Price/Cash Flow 51.2x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.